Wednesday, July 17, 2019 7:10:03 PM
VTv Therapeutics (NASDAQ:VTVT) has risen 8.8% postmarket after it says it will present at this week's Alzheimer's Association International Conference.
The oral presentation will cover data from its phase 3 STEADFAST study and the preceding phase 2B study of azeliragon to "further support the biological hypothesis for the potential beneficial effects of azeliragon on the ADAS-cog and CDR-sb in patients with mild Alzheimer’s disease and type 2 diabetes."
Azeliragon is an orally active small-molecule antagonist of the receptor for advanced glycation endproducts (RAGE).
AVERAGE ANALYSTS PRICE TARGET $6.50
AVERAGE RECOMMENDATION BUY
COMPANY PROFILE
vTv Therapeutics , Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC .
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Recent VTVT News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 09/23/2024 08:28:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:27:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:20:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:17:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:22:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:42:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:38:28 PM
- CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING • PR Newswire (US) • 05/28/2024 12:00:00 PM
- vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 08:51:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:32:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:28:15 PM
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT • PR Newswire (US) • 03/19/2024 12:30:00 PM
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:47:37 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/06/2024 12:52:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 01:04:31 PM
- vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 03/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:26:55 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:14:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:08:30 PM
- vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE • PR Newswire (US) • 02/22/2024 09:00:00 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM